These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Interleukin-1 receptor-associated kinase-M suppresses systemic lupus erythematosus. Lech M; Kantner C; Kulkarni OP; Ryu M; Vlasova E; Heesemann J; Anz D; Endres S; Kobayashi KS; Flavell RA; Martin J; Anders HJ Ann Rheum Dis; 2011 Dec; 70(12):2207-17. PubMed ID: 21875872 [TBL] [Abstract][Full Text] [Related]
9. High frequency of autoantibody-secreting cells and long-lived plasma cells within inflamed kidneys of NZB/W F1 lupus mice. Starke C; Frey S; Wellmann U; Urbonaviciute V; Herrmann M; Amann K; Schett G; Winkler T; Voll RE Eur J Immunol; 2011 Jul; 41(7):2107-12. PubMed ID: 21484784 [TBL] [Abstract][Full Text] [Related]
10. Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black x New Zealand white mice. Response correlates with the absence of an anti-antibody response. Early GS; Zhao W; Burns CM J Immunol; 1996 Oct; 157(7):3159-64. PubMed ID: 8816428 [TBL] [Abstract][Full Text] [Related]
11. [Molecular targets and their regulation in systemic lupus erythematosus and lupus nephritis]. Takasaki Y Nihon Jinzo Gakkai Shi; 2012; 54(5):598-602. PubMed ID: 22991839 [No Abstract] [Full Text] [Related]
12. Treatment with anti-interleukin 23 antibody ameliorates disease in lupus-prone mice. Kyttaris VC; Kampagianni O; Tsokos GC Biomed Res Int; 2013; 2013():861028. PubMed ID: 23841097 [TBL] [Abstract][Full Text] [Related]
13. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Neubert K; Meister S; Moser K; Weisel F; Maseda D; Amann K; Wiethe C; Winkler TH; Kalden JR; Manz RA; Voll RE Nat Med; 2008 Jul; 14(7):748-55. PubMed ID: 18542049 [TBL] [Abstract][Full Text] [Related]
14. Hyperexpression of cyclooxygenase 2 in the lupus immune system and effect of cyclooxygenase 2 inhibitor diet therapy in a murine model of systemic lupus erythematosus. Zhang L; Bertucci AM; Smith KA; Xu L; Datta SK Arthritis Rheum; 2007 Dec; 56(12):4132-41. PubMed ID: 18050205 [TBL] [Abstract][Full Text] [Related]
15. [B-lymphocytes as effectors and regulators in systemic lupus erythematosus]. Winkler TH Z Rheumatol; 2014 May; 73(4):360-2. PubMed ID: 24722870 [No Abstract] [Full Text] [Related]
16. Effect of combining ACE inhibitor and statin in lupus-prone mice. Shimazu H; Kinoshita K; Hino S; Yano T; Kishimoto K; Nagare Y; Nozaki Y; Sugiyama M; Ikoma S; Funauchi M Clin Immunol; 2010 Aug; 136(2):188-96. PubMed ID: 20403731 [TBL] [Abstract][Full Text] [Related]
18. Jak/STAT signaling is involved in the inflammatory infiltration of the kidneys in MRL/lpr mice. Wang S; Yang N; Zhang L; Huang B; Tan H; Liang Y; Li Y; Yu X Lupus; 2010 Sep; 19(10):1171-80. PubMed ID: 20501525 [TBL] [Abstract][Full Text] [Related]
19. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. Lindholm C; Börjesson-Asp K; Zendjanchi K; Sundqvist AC; Tarkowski A; Bokarewa M J Rheumatol; 2008 May; 35(5):826-33. PubMed ID: 18398943 [TBL] [Abstract][Full Text] [Related]
20. Novel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE. Seavey MM; Lu LD; Stump KL; Wallace NH; Ruggeri BA Int Immunopharmacol; 2012 Jan; 12(1):257-70. PubMed ID: 22178195 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]